Search | Search by Center | Search by Source | Keywords in Title
Ratain MJ, Strohbehn GW. Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues? European journal of cancer (Oxford, England : 1990). 2023 Nov 1; 194:113349.
Dose optimisation is increasingly important in oncology, as exemplified by the US Food and Drug Administration''s Project Optimus initiative, which is aligned with similar initiatives in other countries. In parallel, multiple stakeholders have raised concerns about anticancer drug prices, affordability, and access. This is of particular concern to government payers as well as patients and physicians in low- and middle-income countries. As anticancer drugs have historically been approved at the maximally tolerated dose, it is now highly relevant to question whether lower doses are equally effective and can be delivered at lower doses, resulting in less toxicity for patients, and lower costs for patients and payers. We illustrate this opportunity by discussing the combination of atezolizumab and bevacizumab, approved in multiple countries for both non-small cell lung cancer and hepatocellular cancer. Our conclusion is that the cost of this regimen can be reduced by more than 80%, an opportunity that should be considered by patients, prescribers, payers, and policymakers.